Hyper-expensive new therapies and the prioritisation of R&D (original) (raw)

Hyper-expensive Treatments: Background paper

David Hunter

View PDFchevron_right

Ethics roundtable: Using new, expensive drugs

Richard Burrows

Critical care (London, England), 2002

View PDFchevron_right

Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access

Richard Maziarz

Stem cells translational medicine, 2017

View PDFchevron_right

Treatment Is Worth a Lot - But Just How Much

Denis Horgan

Biomedicine Hub, 2017

View PDFchevron_right

Medical paternalism and expensive unsubsidised drugs

Julian Savulescu

View PDFchevron_right

Access to high cost medicines in Australia: ethical perspectives

Christine Lu

Australia and New Zealand Health Policy, 2008

View PDFchevron_right

A pill too hard to swallow: how the NHS is limiting access to high priced drugs

Jonathan Gornall

BMJ, 2016

View PDFchevron_right

Ethics of clinical trials: the ‘forbidden fruit’ phenomena

Hazel Thornton

Breast, 1996

View PDFchevron_right

Fair Pricing of Innovative Medicines: An EHA Position Paper

John Gribben

HemaSphere, 2020

View PDFchevron_right

Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion

Dimitris Athanasiou

Biomedicine Hub

View PDFchevron_right

How Should Therapeutic Decisions about Expensive Drugs Be Made in Imperfect Environments?

Leonard Fleck

AMA journal of ethics, 2017

View PDFchevron_right

Ethical Perspectives on Costly Drugs and Health Care

Amy Tsou

Neurology, 2021

View PDFchevron_right

Clinical and Ethical Perspectives on Rationing of High-Cost Drugs

Vincent Giannetti

Annals of Pharmacotherapy, 1995

View PDFchevron_right

A human rights-based approach to the reimbursement of expensive medicines

Brigit Toebes

Bulletin of the World Health Organization, 2016

View PDFchevron_right

Regulating innovative treatments: information, risk allocation and redress

Tina Cockburn

Law, Innovation and Technology

View PDFchevron_right

The Bio-Economy: A Challenge to the Integrity of Medicine and Healthcare

Leonardo De Castro

Asian Bioethics Review, 2014

View PDFchevron_right

Australia and New Zealand Health Policy BioMed Central Commentary Access to high cost medicines in Australia: ethical perspectives

Christine Lu

2008

View PDFchevron_right

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

Andrew Lo

JAMA Otolaryngology–Head & Neck Surgery, 2014

View PDFchevron_right

Just caring: Assessing the ethical and economic costs of personalized medicine

Leonard Fleck

Urologic Oncology: Seminars and Original Investigations, 2014

View PDFchevron_right

Fair funding of extraordinarily expensive medication

Leonard Fleck

Bioethica Forum, 2011

View PDFchevron_right

Rare diseases: Should healthcare policy-makers relax their normal criteria in the case of rare diseases, when deciding whether to licence and fund treatments for them

Sean Sinclair

View PDFchevron_right

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Guenka Petrova

Frontiers in Public Health

View PDFchevron_right

Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies

Alan Haycox

Pharmacoeconomics, 2008

View PDFchevron_right

The legal imperative for treating rare disorders

Jeremy Christ Manuel

Orphanet Journal of Rare Diseases, 2013

View PDFchevron_right

Cancer medicines: a private vice for public benefit

Richard Sullivan

eCancer, 2024

View PDFchevron_right